Page last updated: 2024-12-07
uk 21
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
UK 21: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 131785 |
| SCHEMBL ID | 9768757 |
| MeSH ID | M0209524 |
Synonyms (11)
| Synonym |
|---|
| 134423-92-0 |
| 2',3',5'-tris-o-(n -(2-n-propyl-n-pentanoyl)glycyl)-5-fluorouridine |
| glycine, n-(1-oxo-2-propylpentyl)-, triester with 5-fluorouridine |
| uk 21 |
| uk-21 |
| [(2r,3r,4r,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-bis[[2-(2-propylpentanoylamino)acetyl]oxy]oxolan-2-yl]methyl 2-(2-propylpentanoylamino)acetate |
| SCHEMBL9768757 |
| DTXSID20158693 |
| 2',3',5'-tris-o-[n-(2-n-propyl-n-pentanoyl)glycyl]-5-fluorouridine |
| uk21 |
| 2',3',5'-tris-o-(n-(2-n-propyl-n-pentanoyl)glycyl)-5-fluorouridine |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the bioavailability of UK-21 given orally did not seem to be good." | ( Novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21: antitumor activity and effect on humoral immune response in mice. Kaku, Y; Kita, J; Koda, A; Maeda, D; Mori, H; Nagai, H; Nakayama, K, 1994) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 56.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||